bioAffinity Technologies (BIAF) Cash & Current Investments (2022 - 2025)
bioAffinity Technologies (BIAF) has disclosed Cash & Current Investments for 4 consecutive years, with $6.4 million as the latest value for Q4 2025.
- Quarterly Cash & Current Investments rose 479.03% to $6.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $6.4 million through Dec 2025, up 479.03% year-over-year, with the annual reading at $6.4 million for FY2025, 479.03% up from the prior year.
- Cash & Current Investments for Q4 2025 was $6.4 million at bioAffinity Technologies, down from $7.7 million in the prior quarter.
- The five-year high for Cash & Current Investments was $13.5 million in Q3 2022, with the low at $444706.0 in Q1 2025.
- Average Cash & Current Investments over 4 years is $5.1 million, with a median of $3.7 million recorded in 2023.
- The sharpest move saw Cash & Current Investments crashed 90.36% in 2024, then surged 858.65% in 2025.
- Over 4 years, Cash & Current Investments stood at $11.4 million in 2022, then crashed by 75.28% to $2.8 million in 2023, then tumbled by 60.83% to $1.1 million in 2024, then surged by 479.03% to $6.4 million in 2025.
- According to Business Quant data, Cash & Current Investments over the past three periods came in at $6.4 million, $7.7 million, and $802835.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.